JP2011502521A - Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法 - Google Patents

Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法 Download PDF

Info

Publication number
JP2011502521A
JP2011502521A JP2010533337A JP2010533337A JP2011502521A JP 2011502521 A JP2011502521 A JP 2011502521A JP 2010533337 A JP2010533337 A JP 2010533337A JP 2010533337 A JP2010533337 A JP 2010533337A JP 2011502521 A JP2011502521 A JP 2011502521A
Authority
JP
Japan
Prior art keywords
polypeptide
r2gp140
fusion polypeptide
fusion
trimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010533337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502521A5 (https=
Inventor
ジェラルド クイナン，
クリストファー ブロダー，
Original Assignee
ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド filed Critical ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド
Publication of JP2011502521A publication Critical patent/JP2011502521A/ja
Publication of JP2011502521A5 publication Critical patent/JP2011502521A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010533337A 2007-11-12 2008-11-12 Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法 Pending JP2011502521A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98728707P 2007-11-12 2007-11-12
PCT/US2008/083190 WO2009102357A2 (en) 2007-11-12 2008-11-12 Hiv-1 envelope glycoprotein oligomer and methods of use

Publications (2)

Publication Number Publication Date
JP2011502521A true JP2011502521A (ja) 2011-01-27
JP2011502521A5 JP2011502521A5 (https=) 2011-11-17

Family

ID=40957413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533337A Pending JP2011502521A (ja) 2007-11-12 2008-11-12 Ｈｉｖ−１外被糖タンパク質オリゴマー及び使用方法

Country Status (6)

Country Link
US (1) US8597658B2 (https=)
EP (1) EP2235065A4 (https=)
JP (1) JP2011502521A (https=)
AU (1) AU2008350273B2 (https=)
CA (1) CA2705373A1 (https=)
WO (1) WO2009102357A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138581A (ja) * 2012-07-26 2018-09-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
JP2019522626A (ja) * 2016-05-02 2019-08-15 ザ スクリプス リサーチ インスティテュート Ｈｉｖ−１免疫原に関連した組成物および方法
JP2020503839A (ja) * 2017-11-17 2020-02-06 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522039A (ja) * 1998-08-04 2002-07-23 ザ ヘンリー エム． ジャクソン ファウンデイション 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション
WO2006026508A2 (en) * 2004-08-27 2006-03-09 The Henry M. Jackson Foundation Modified hiv-1 envelope proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
EP1214333A4 (en) * 1999-09-17 2005-01-19 Dana Farber Cancer Inst Inc SOLUBLE STABILIZED GLYCOPROTEIN TRIMERS
WO2003077838A2 (en) * 2002-03-05 2003-09-25 National Institutes Of Health Office Of Technology Transfer Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522039A (ja) * 1998-08-04 2002-07-23 ザ ヘンリー エム． ジャクソン ファウンデイション 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション
WO2006026508A2 (en) * 2004-08-27 2006-03-09 The Henry M. Jackson Foundation Modified hiv-1 envelope proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013041724; Ｊ．　Ｖｉｒｏｌ．，　２００３，　ｖｏｌ．７７，　ｎｏ．５，　ｐ．３１１９-３１３０ *
JPN6013041725; Ｊ．　Ｖｉｒｏｌ．，　２００２，　ｖｏｌ．７６，　ｎｏ．９，　ｐ．４６３４-４６４２ *
JPN6013041726; Ｊ．　Ｖｉｒｏｌ．，　２０００，　ｖｏｌ．７４，　ｎｏ．１０，　ｐ．４７４６-４７５４ *
JPN6013041727; Ｊ．　Ｖｉｒｏｌ．，　２０００，　ｖｏｌ．７４，　ｎｏ．１２，　ｐ．５７１６-５７２５ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138581A (ja) * 2012-07-26 2018-09-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 多量体融合タンパク質ワクチン及び免疫療法
JP2019522626A (ja) * 2016-05-02 2019-08-15 ザ スクリプス リサーチ インスティテュート Ｈｉｖ−１免疫原に関連した組成物および方法
JP7046832B2 (ja) 2016-05-02 2022-04-04 ザ スクリプス リサーチ インスティテュート Ｈｉｖ－１免疫原に関連した組成物および方法
JP2020503839A (ja) * 2017-11-17 2020-02-06 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原
JP2022022308A (ja) * 2017-11-17 2022-02-03 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原
JP2023057154A (ja) * 2017-11-17 2023-04-20 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原
JP7615190B2 (ja) 2017-11-17 2025-01-16 グリフォルス ダイアグノステック ソリューションズ インコーポレーテッド 哺乳類で発現した新規なヒト免疫不全ウイルスエンベロープタンパク質抗原

Also Published As

Publication number Publication date
WO2009102357A2 (en) 2009-08-20
AU2008350273A1 (en) 2009-08-20
EP2235065A4 (en) 2011-09-28
CA2705373A1 (en) 2009-08-20
AU2008350273B2 (en) 2014-04-10
US8597658B2 (en) 2013-12-03
US20100316661A1 (en) 2010-12-16
EP2235065A2 (en) 2010-10-06
WO2009102357A3 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
US20230285539A1 (en) Vaccines against sars-cov-2 and other coronaviruses
CN112638411B (zh) 疫苗组合物
KR102506895B1 (ko) 안정화된 용해성 융합-전 rsv f 단백질
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
CN105792842A (zh) 埃巴病毒疫苗
CN114127101A (zh) 用于治疗或预防呼吸道感染的亚单位疫苗
WO2014018858A2 (en) Multimeric fusion protein vaccine and immunotherapeutic
WO2014031694A2 (en) Anti-tau antibodies and methods of making and using in treatment of tauopathies
CN111542534B (zh) 新型支架式hiv-1疫苗免疫原
KR20250034197A (ko) 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
CA3189465A1 (en) Improved coronavirus vaccine
KR20190012193A (ko) 안정화된 융합-전 rsv f 단백질
Benen et al. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
EP3004173B1 (en) Single domain antibody display
PH12015500890B1 (en) Vaccine for preventing porcine edema disease
CN114621356A (zh) 以il18为分子佐剂的带状疱疹亚单位疫苗
WO2022162012A2 (en) Antibodies broadly targeting coronaviruses and uses thereof
US8597658B2 (en) HIV-1 envelope glycoprotein oligomer and methods of use
US20240307524A1 (en) Coronavirus vaccines
US8475799B2 (en) HIV-1 GP41 neutralization domain and use thereof
WO2014188212A2 (en) Treatment and prevention of malaria
WO2022161598A1 (en) Antibodies broadly targeting coronaviruses and uses thereof
CN116745408A (zh) 稳定的冠状病毒刺突蛋白融合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140408